九芝堂(000989) - 2022 Q3 - 季度财报

Financial Performance - Revenue for Q3 2022 was ¥574,210,785.75, a decrease of 37.13% compared to the same period last year[6] - Net profit attributable to shareholders was ¥22,878,124.55, down 54.95% year-on-year[6] - Basic earnings per share decreased by 55.13% to ¥0.0267[6] - Total operating revenue for the current period was ¥2,463,382,341.61, a decrease of approximately 17.6% compared to ¥2,991,687,263.36 in the previous period[25] - Total operating costs decreased to ¥2,217,629,799.25 from ¥2,644,394,014.86, reflecting a reduction of about 16.1%[25] - Net profit for the current period was ¥388,794,815.90, an increase of approximately 45% from ¥267,989,953.45 in the previous period[27] - Earnings per share (EPS) for the current period was ¥0.4572, compared to ¥0.3165 in the previous period, indicating a growth of about 44.4%[30] - The company experienced a decrease in comprehensive income attributable to the parent company, totaling ¥373,677,043.63 compared to ¥271,093,059.45 in the previous period[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,168,693,344.32, a decrease of 1.84% from the end of the previous year[6] - The company's total assets as of September 30, 2022, amount to ¥5,168,693,344.32, a decrease from ¥5,265,533,999.97 at the beginning of the year[21] - The total current assets are ¥2,724,718,318.81, slightly down from ¥2,762,415,779.24 at the start of the year[21] - The company's inventory as of September 30, 2022, is valued at ¥626,478,631.16, down from ¥809,992,645.08 earlier in the year[21] - The total liabilities amounted to ¥1,160,235,227.30, a decrease from ¥1,295,295,908.59, reflecting a reduction of about 10.4%[25] - The total liabilities include accounts payable of ¥53,628,846.13, down from ¥191,476,513.42 at the beginning of the year[21] - The company’s total current liabilities include contract liabilities of ¥49,614,389.99, down from ¥83,967,683.23 at the beginning of the year[21] Cash Flow - Cash flow from operating activities decreased by 13.47% to ¥378,827,633.83 year-to-date[6] - Cash flow from operating activities was ¥2,239,769,086.14, down from ¥3,046,096,911.60, representing a decline of approximately 26.5%[31] - Operating cash inflow totaled CNY 2,276,349,290.72, down from CNY 3,089,951,401.48, representing a decrease of approximately 26.3% year-over-year[34] - Operating cash outflow amounted to CNY 1,897,521,656.89, a decrease from CNY 2,652,156,278.71, reflecting a reduction of about 28.5% year-over-year[34] - Net cash flow from operating activities was CNY 378,827,633.83, compared to CNY 437,795,122.77, indicating a decline of approximately 13.4% year-over-year[34] - Cash inflow from investment activities was CNY 1,636,580,096.48, down from CNY 2,848,621,763.01, a decrease of around 42.6% year-over-year[34] - Net cash flow from investment activities was -CNY 598,740,917.76, compared to -CNY 527,184,364.41, showing an increase in cash outflow year-over-year[34] - Cash inflow from financing activities was CNY 30,000.00, significantly lower than CNY 80,000,000.00 from the previous period[34] - Cash outflow from financing activities totaled CNY 361,093,945.95, down from CNY 477,542,407.25, reflecting a decrease of approximately 24.4% year-over-year[34] - The net increase in cash and cash equivalents was -CNY 580,977,229.88, compared to -CNY 486,931,648.89, indicating a worsening cash position year-over-year[34] - The ending balance of cash and cash equivalents was CNY 227,103,425.45, down from CNY 307,851,025.97, a decrease of about 26.2% year-over-year[34] Shareholder Information - The total equity attributable to shareholders increased by 1.06% to ¥4,011,342,273.09 compared to the previous year[6] - The total equity attributable to shareholders of the parent company increased to ¥4,011,342,273.09 from ¥3,969,190,507.07, showing a growth of approximately 1.1%[25] - The total number of common shareholders at the end of the reporting period is 46,117, with the top 10 shareholders holding a combined 56.83% of shares[14] - Li Zhenguo is the largest shareholder, holding 25.73% of shares, amounting to 223,661,171 shares, with 197,556,278 shares pledged[14] Investment and Development - The company reported a significant increase in other receivables by 1575.47% to ¥15,854.82 million, mainly due to equity transfer payments[11] - Investment income increased by 610.71% to ¥22,221.49 million, attributed to the transfer of equity stakes[13] - The company’s financial expenses decreased by 85.50% to ¥48.67 million, due to increased interest income and reduced financing costs[13] - The company has received approval for clinical trials of a new drug, YB209, indicating ongoing research and development efforts[18] - The company plans to expand its market presence and enhance product development in the upcoming quarters[12] Audit Information - The company did not undergo an audit for the third quarter report[37]